hs-CRP/HDL-C Ratio Tracks With Faster Kidney Function Loss in Older Chinese Adults

A composite marker built from inflammation and lipid metabolism may help identify older adults drifting toward chronic kidney disease before the usual clinical signals appear. In a longitudinal analysis from the China Health and Retirement Longitudinal Study, a higher baseline high-sensitivity C-reactive protein to high-density lipoprotein cholesterol ratio was associated with a greater risk of both rapid kidney function decline and incident low eGFR among Chinese older adults free of CKD at baseline.

The signal matters because the ratio captures two biologically relevant processes at once. hs-CRP reflects systemic inflammation, while HDL-C is often treated as a marker of protective lipid transport and vascular resilience. When inflammatory burden rises and HDL-C is comparatively lower, the kidney is exposed to a milieu that can accelerate microvascular injury, endothelial dysfunction, and progressive nephron stress. In practical terms, the ratio may be telling clinicians more about renal vulnerability than either biomarker alone.

A Composite Marker Outperformed Simple Risk Intuition

The study linked the baseline hs-CRP/HDL-C ratio with later renal outcomes using multivariable regression models that adjusted for potential confounders. Participants in the highest quartile faced a significantly increased risk of both outcomes compared with those in the lowest quartile, and the association persisted after accounting for traditional metabolic risk factors. The relationship was not a one-off statistical curiosity; it followed an overall positive correlation across outcomes.

One sentence captures the clinical tension here. The kidney can be deteriorating long before overt CKD is recognized.

That is what makes a composite biomarker attractive. eGFR decline often unfolds quietly in older adults, especially when hypertension, dyslipidemia, glucose abnormalities, and chronic low-grade inflammation overlap. A marker that condenses inflammatory and lipid information into a single ratio may be easier to interpret than a broad panel of loosely connected lab values, particularly in primary care settings where early renal risk stratification is often limited by time and competing demands.

Why Inflammation and Lipids Converge at the Kidney

The biological logic is straightforward. Chronic inflammation promotes endothelial activation, oxidative stress, and glomerular and tubular damage, while impaired HDL biology may weaken reverse cholesterol transport and anti-inflammatory defenses. In older adults, these processes do not operate in isolation. They reinforce one another, and the kidney is especially vulnerable because it sits at the intersection of high blood flow, delicate microvasculature, and long-term metabolic stress.

This is also consistent with the growing concept of cardiovascular-kidney-metabolic syndrome, in which vascular injury, metabolic dysfunction, and renal decline move together rather than as separate diseases. A marker like hs-CRP/HDL-C may therefore have value not because it is kidney-specific, but because it reflects a broader pathophysiologic state in which renal decline becomes more likely. In older adults, that broader state may be exactly what clinicians need to detect early.

Renal Risk Stratification May Start Earlier Than eGFR Alone

The study focused on older adults without CKD at baseline, which gives the findings real preventive relevance. Once CKD is established, clinicians are often forced into damage control: blood pressure optimization, glycemic control, medication review, and surveillance for further loss of filtration. A biomarker associated with incident low eGFR and rapid decline offers a different opportunity, one centered on risk detection before the threshold for disease is crossed.

This does not turn the hs-CRP/HDL-C ratio into a standalone diagnostic test. It does suggest that the ratio could complement routine assessment in older adults who may otherwise appear stable. Someone with a relatively preserved eGFR today may still be on a trajectory toward kidney decline if systemic inflammation is persistent and lipid protection is impaired. The ratio could help identify that trajectory earlier, when preventive interventions still have the greatest chance of altering course.

What the Association Can and Cannot Prove

Observational data do not establish causality, and this study does not claim that lowering the hs-CRP/HDL-C ratio will slow renal decline. The association may reflect broader cardiometabolic risk rather than a direct mechanistic trigger. Still, the fact that the link remained after multivariable adjustment suggests the ratio contains independent information beyond the usual metabolic checklist.

That independence is clinically useful. It means the marker may capture a risk phenotype that is not fully explained by conventional variables. In older adults, where multiple comorbidities can blur the picture, such a phenotype may help distinguish patients who merit closer renal surveillance from those with lower near-term risk.

The study also reinforces a broader theme in nephrology: kidney decline is often the downstream expression of systemic biology. Inflammation, lipid dysfunction, and vascular injury rarely announce themselves with a single dramatic event. They accumulate, quietly and cumulatively, until filtration loss becomes measurable.

What Clinicians May Take From the Signal

The findings support a more integrated view of renal prevention in older adults. hs-CRP and HDL-C are already familiar laboratory measures in many clinical settings, and combining them into a ratio could offer a low-cost way to refine risk assessment. For aging populations at risk of CKD, especially those with overlapping metabolic and cardiovascular stressors, the ratio may deserve attention as an early warning marker.

Even so, implementation should remain cautious. The current evidence supports association, not intervention. Before the ratio can move into routine decision-making, prospective validation and studies linking biomarker change to clinical benefit will be needed. For now, the most defensible reading is narrower: in Chinese older adults, a higher hs-CRP/HDL-C ratio marked a greater likelihood of rapid kidney function decline and incident low eGFR, independent of traditional metabolic risk factors.

Trial Identifier and Article Record

The article appears in Scientific Reports and is indexed with DOI 10.1038/s41598-026-80324-4. The publication offers a clear epidemiologic signal, but it leaves the next clinical question unresolved: whether modifying the inflammatory-lipid profile that the ratio reflects can actually slow renal deterioration before CKD takes hold.


Reporting by Dr. A. Nikhil Krishnan, MBBS for Medicine World Foundation, with additional data provided by Nature Medical Research.
PRIMARY CLINICAL EVIDENCE & REGISTRY DATA